Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter

Financial Information

Here you will find a summary of Ironwood Pharmaceuticals, Inc.'s latest financial information.

Latest Annual Report/10-K

Form	Filing date	View
10-K	Feb 07, 2014	View HTML 0001047469-14-000693.pdf 0001047469-14-000693.rtf 0001047469-14-000693.xls EX-101.INS - EX-101.INS

Latest Proxy Statement

Form	Filing date	View
DEF 14A	Apr 17, 2015	View HTML 0001047469-15-003640.pdf 0001047469-15-003640.rtf 0001047469-15-003640.xls
DEF 14A	Apr 15, 2016	View HTML 0001047469-16-012253.pdf 0001047469-16-012253.rtf 0001047469-16-012253.xls
DEF 14A	Apr 12, 2013	View HTML 0001047469-13-004276.pdf 0001047469-13-004276.rtf 0001047469-13-004276.xls

Ironwood Pharmaceuticals
301 Binney Street
Cambridge, MA 02142

tel 617.621.7722
fax 617.494.0480

ABOUT US

Pharmaceutical
Advisory Committee

Transparency

Patient Assistance

Our MEDICINES

Overview

Discovery of Linaclotide

R&D

COLLABORATE

Accessing Additional Products

Globalization

Investors

NEWS

Join US

LINZESS® is a registered trademark of Ironwood Pharmaceuticals, Inc., ZURAMPIC®, DUZALLO® are registered trademarks of AstraZeneca AB Corporation or its affiliates and are used herein under license.

Market Capitalization (Mil)	$2,559.26
Shares Outstanding (Mil)	$153.16
Shares Outstanding, Average (FY) (Mil)	$148.99
Float (Mil)	$138.57

Financial Information

Latest Earnings Release and 10-Q

Latest Annual Report/10-K

Latest Proxy Statement

Share Related